
|Articles|March 9, 2010
you tube on survivorship
Advertisement
Topic overview from Lisa Diller, MD, Director, Perini Quality-of-Life Program, Dana-Farber Cancer Institute
Advertisement
Related Content
Advertisement




89 Imlunestrant With or Without Abemaciclib as First- and Second-Line Therapy in Advanced Breast Cancer (ABC): A Subgroup Analysis From the EMBER-3 Trial
ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos

Advertisement
Advertisement
Trending on CancerNetwork
1
Concomitant COVID-19 Vaccination Tied to Improved OS with Immunotherapy
2
FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC
3
Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma
4
Exercise Regimens Could Disrupt Accelerated Cellular Aging in Cancer
5
























































